Heterozygous deletion of the PU.1 locus in human AML

Blood

Volumn 115, Issue 2, 2010, Pages 331-334

  Bonadies, Nicola ^a   Pabst, Thomas ^a   Mueller, Beatrice U ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD11B ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; HEMOGLOBIN; HLA DR3 ANTIGEN; LACTATE DEHYDROGENASE; MICROSOMAL AMINOPEPTIDASE; TRANSCRIPTION FACTOR PU 1; ONCOPROTEIN; PROTO ONCOGENE PROTEIN SPI 1; PROTO-ONCOGENE PROTEIN SPI-1; TRANSACTIVATOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLAST CELL; BONE MARROW; CANCER CHEMOTHERAPY; CELL INFILTRATION; CONTROLLED STUDY; CYTOGENETICS; EXON; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENE SEGREGATION; HEMOGLOBIN BLOOD LEVEL; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; INTRON; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; UPSTREAM REGULATORY ELEMENT; BIOSYNTHESIS; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOTE; MALE; METABOLISM; QUANTITATIVE TRAIT LOCUS;

FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HETEROZYGOTE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LOSS OF HETEROZYGOSITY; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; QUANTITATIVE TRAIT LOCI; SEQUENCE DELETION; TRANS-ACTIVATORS;

EID: 75649087061     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-212225     Document Type: Article

References (23)

1. Scott EW, Simon MC, Anastasi J, et al. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science. 1994;265(5178):1573-1577.
2. McKercher SR, Torbett BE, Anderson KL, et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J. 1996;15(20):5647-5658.
3. Anderson KL, Smith KA, Conners K, et al. Myeloid development is selectively disrupted in PU.1 null mice. Blood. 1998;91(10):3702-3710.
4. Nutt SL, Metcalf D, D'Amico A, Wu L. Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors. J Exp Med. 2005;201(2): 221-231.
5. Rosenbauer F, Tenen DG. Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol. 2007;7(2): 105-117.
6. Friedman AD. Transcriptional regulation of granulocyte and monocyte development. Oncogene. 2002;21(21):3377-3390.
7. Dekoter RP, Kamath MB, Houston IB. Analysis of concentration-dependent functions of PU.1 in hematopoiesis using mouse models. Blood Cells Mol Dis. 2007;39(3):316-320.
8. Rosenbauer F, Koschmieder S, Steidl U, Tenen DG. Effect of transcription-factor concentrations on leukemic stem cells. Blood. 2005;106(5):1519-1524.
9. Pabst T, Mueller BU. Transcriptional dysregulation during myeloid transformation in AML. Oncogene. 2007;26(47):6829-6837.
10. Mueller BU, Pabst T, Fos J, et al. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood. 2006;107(8):3330-3338.
11. Vangala RK, Heiss-Neumann MS, Rangatia JS, et al. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood. 2003;101(1):270-277.
12. Mueller BU, Pabst T, Osato M, et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood. 2002;100(3):998-1007.
13. Lamandin C, Sagot C, Roumier C, et al. Are PU.1 mutations frequent events in acute myeloid leukemia (AML)? Blood. 2002;100(13):4680-4681.
14. Vegesna V, Takeuchi S, Hofmann WK, et al. C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. Leuk Res. 2002; 26(5):451-457.
15. Dohner K, Tobis K, Bischof T, et al. Mutation analysis of the transcription factor PU.1 in younger adults (16 to 60 years) with acute myeloid leukemia: a study of the AML Study Group Ulm (AMLSG ULM). Blood. 2003;102(10):3850.
16. Mueller BU, Pabst T, Hauser P, et al. Mutations of the transcription factor PU.1 are not associated with acute lymphoblastic leukaemia. Br J Cancer. 2006;94(12):1918-1920.
17. Li Y, Okuno Y, Zhang P, et al. Regulation of the PU.1 gene by distal elements. Blood. 2001; 98(10):2958-2965.
18. Okuno Y, Huang G, Rosenbauer F, et al. Potential autoregulation of transcription factor PU.1 by an upstream regulatory element. Mol Cell Biol. 2005; 25(7):2832-2845.
19. Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet. 2004;36(6):624-630.
20. Rosenbauer F, Owens BM, Yu L, et al. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet. 2006;38(1):27-37.
21. Steidl U, Steidl C, Ebralidze A, et al. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest. 2007;117(9):2611-2620.
22. Steidl C, Simon R, Bürger H, et al. Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urothelium. J Pathol. 2002; 198(1):115-120.
23. Suraweera N, Meijne E, Moody J, et al. Mutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukemia. Oncogene. 2005;24(22):3678-3683.